Beyond Air, Inc.
Close on Oct 19, 2026
- Market cap
- $1.54M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jun 30, 2026 | Aug 18, 2026 | After market close | $1.80M | $-11.00 | – |
| Q4 FY2026 Ended Mar 31, 2026 | Jun 26, 2026 | After market close | $1.90M | $-0.77 | – |
| Q3 FY2026 Ended Dec 31, 2025 | Feb 13, 2026 | After market close | $2.20M | $-0.85 | – |
| Q2 FY2026 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | $1.80M | $-1.25 | – |
| Q1 FY2026 Ended Jun 30, 2025 | Aug 18, 2025 | After market close | $1.80M | $-1.53 | – |
| Q4 FY2025 Ended Mar 31, 2025 | Jun 18, 2025 | After market close | $1.15M | $-0.09 | – |
| Q3 FY2025 Ended Dec 31, 2024 | Feb 14, 2025 | After market close | $1.10M | $-0.15 | – |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 18, 2024 | After market close | $800.00K | $-0.28 | – |
| Q1 FY2025 Ended Jun 30, 2024 | Aug 9, 2024 | After market close | $700.00K | $-0.27 | – |
| Q4 FY2024 Ended Mar 31, 2024 | Jun 27, 2024 | After market close | – | – | – |
| Q3 FY2024 Ended Dec 31, 2023 | Feb 16, 2024 | After market close | $400.00K | $-0.50 | – |
Company guidance
Outlook given with results on Aug 18, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue guidance | calendar year 2026 | $8.00M | Maintained |
| revenue guidance | 2027 | $16.00M to $18.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Beyond Air filed with the SEC
Air ® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Air ® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Results of operations · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
Other events · EX-99.1 to Form 8-K
Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning
Other events · EX-99.1 to Form 8-K
Air® Appoints Dan Moorhead as Chief Financial Officer
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Air ® Announces Transition of Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Air® Secures Up to $32 Million to Accelerate Growth
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
Regulation FD disclosure · EX-99.1 to Form 8-K
Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Air Submits FDA PMA Supplement for Next Generation LungFit® PH
Results of operations · Executive or director change · Other events · EX-99.2 to Form 8-K
in Funding to Advance Development of an Innovative Autism Therapy
Material agreement · Other events · EX-99.1 to Form 8-K
Air Announces Agreements Expanding Global Distribution of LungFit® PH
Executive or director change · Other events · EX-99.1 to Form 8-K
Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Beyond Air ® Granted 180-Day Extension by
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Air Receives CE Mark in Europe for the LungFit® PH System
Other events · EX-99.1 to Form 8-K
Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Air ® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Listing notice · Executive or director change · EX-99.1 to Form 8-K
Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
Air® Appoints David Webster as Chief Commercial Officer
Other events · EX-99.1 to Form 8-K
Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Air ® Reports Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Second Quarter of Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Air ® and Getz Healthcare Enter Strategic Collaboration to
Other events · EX-99.1 to Form 8-K
First Quarter of Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Air ® Reports Financial Results
Results of operations · EX-99.1 to Form 8-K
Air® Secures up to $40 Million Debt Financing
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Air ® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer
Other events · EX-99.1 to Form 8-K
the Third Quarter of Fiscal Year 2023
Results of operations · EX-99.1 to Form 8-K
the Second Quarter of Fiscal Year 2023
Results of operations · Other events · EX-99.1 to Form 8-K
Cancer ™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination
Results of operations · Other events · EX-99.2 to Form 8-K